Jun 2026 (Q2 FY26) — Aug 4, 2026
BioNTech Q2 FY26 — Leadership Transition and Pipeline Advancement Amidst Revised Guidance
Read the full callBioNTech (BNTX) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
BioNTech earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Guidance
What management said, and what became of it
16 of 22 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| BNT324 Phase III trial in 1L mCRPC | Begin recruitment | Dec 2025 | This quarter, we dosed our first patient in the Phase III clinical trial for Elfe-D, evaluating it against docetaxel in patients with [indiscernible] metastatic castration-resistant prostate cancer. | Achieved |
| BNT323 endometrial cancer data | Share data | Sep 2024 | Ghosted | |
| Binding agreement for new mRNA company | Sign binding agreement | Dec 2025 | On a final note, regarding the announcement of new company and potential contributions by BioNTech, the discussions are ongoing. | Delayed |
6 of BioNTech SE's 47 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 44 more targets are in the full ledger.
Claimed
- Pumitamig Phase II data in first-line NSCLC demonstrated robust clinical activity with 72.5% unconfirmed ORR and 62.5% confirmed ORR.
- Gotistobart showed durable disease control with a 12-month PFS rate of 25% compared to 0% for docetaxel in metastatic squamous NSCLC.
- The company maintained a strong financial position with EUR 16.6 billion in cash, cash equivalents, and security investments.
- Initiated a share repurchase program, having repurchased EUR 162 million to date.
Qualified
- Q2 FY26 revenues declined to EUR 106 million from EUR 261 million in the prior year, primarily due to lower COVID-19 vaccine demand.
- Full-year 2026 revenue guidance was revised down to EUR 1.6 billion - EUR 1.9 billion.
- Adjusted R&D expenses decreased to EUR 477 million from EUR 509 million, reflecting disciplined prioritization.
- Adjusted SG&A expenses increased to EUR 198 million from EUR 137 million, driven by scaling processes and prelaunch activities.
- Readouts for pumitamig Phase III in TNBC and gotistobart Phase II in CRPC were pushed to 2027.
Price
$89.21 +1.71% · +$1.5
Performance −15.2% 1Y
1Y: $105.14 on 17 Oct 2025 → $89.21. High $119.34 (27 Jan 2026), low $83.89 (10 Mar 2026).
- Previous close
- $87.71
- 52-week range
- $83.89 – $119.34
- One year
- −17.36%
Overview
- Symbol
- BNTX
- Sector
- Health Care
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
16 of 22 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| BNT324 Phase III trial in 1L mCRPC | Begin recruitment | Dec 2025 | This quarter, we dosed our first patient in the Phase III clinical trial for Elfe-D, evaluating it against docetaxel in patients with [indiscernible] metastatic castration-resistant prostate cancer. | Achieved |
| BNT323 endometrial cancer data | Share data | Sep 2024 | Ghosted | |
| Binding agreement for new mRNA company | Sign binding agreement | Dec 2025 | On a final note, regarding the announcement of new company and potential contributions by BioNTech, the discussions are ongoing. | Delayed |
Claimed
- Pumitamig Phase II data in first-line NSCLC demonstrated robust clinical activity with 72.5% unconfirmed ORR and 62.5% confirmed ORR.
- Gotistobart showed durable disease control with a 12-month PFS rate of 25% compared to 0% for docetaxel in metastatic squamous NSCLC.
- The company maintained a strong financial position with EUR 16.6 billion in cash, cash equivalents, and security investments.
- Initiated a share repurchase program, having repurchased EUR 162 million to date.
Qualified
- Q2 FY26 revenues declined to EUR 106 million from EUR 261 million in the prior year, primarily due to lower COVID-19 vaccine demand.
- Full-year 2026 revenue guidance was revised down to EUR 1.6 billion - EUR 1.9 billion.
- Adjusted R&D expenses decreased to EUR 477 million from EUR 509 million, reflecting disciplined prioritization.
- Adjusted SG&A expenses increased to EUR 198 million from EUR 137 million, driven by scaling processes and prelaunch activities.
- Readouts for pumitamig Phase III in TNBC and gotistobart Phase II in CRPC were pushed to 2027.
The full ledger
Open BioNTech SE’s full ledger
A free account opens 5 company ledgers a month. All 47 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
BioNTech Q1 FY26 — Oncology Pipeline Advancement and Share Buyback
Read the full callDec 2025 (Q4 FY25) — Mar 10, 2026
BioNTech Q4 FY25 — Strong Financials and Strategic Pipeline Advancement Amidst Leadership Transition
Read the full callEvery analysed call
BioNTech earnings calls (BNTX)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 442 | 342 | 1,162 | 4,459 | 3,438 | 3,050 | 3,240 | 3,248 |
| Fixed assets | 76 | 105 | 279 | 365 | 650 | 837 | 972 | 1,270 |
| Total assets | 748 | 896 | 2,845 | 17,930 | 24,829 | 25,422 | 23,406 | 25,837 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -67 | -223 | -17 | 1,008 | 14,482 | 5,935 | 216 | 536 |
| Cash from investing | -76 | -87 | -178 | -641 | -38 | -7,685 | -2,162 | -2,900 |
| Cash from financing | 418 | 431 | 1,098 | 107 | -1,514 | -860 | -48 | -62 |
| Capital expenditure | -34 | -43 | -81 | -144 | -351 | -276 | -298 | -206 |
| Free cash flow | -102 | -266 | -98 | 863 | 14,131 | 5,660 | -82 | 330 |
Insider filings
27 filings between Apr 22, 2026 and Oct 9, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$89.76M
27 sales by 2 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Sahin Ugur | — | $84.23M | Oct 9, 2026 |
| Poetting Sierk | — | $5.53M | Apr 22, 2026 |
Latest filings (27)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 36,209 | $3.45M |
| Oct 8, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 27,000 | $2.49M |
| Oct 7, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 24,000 | $2.30M |
| Oct 6, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 21,000 | $2.03M |
| Oct 5, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 72,000 | $7.00M |
| Oct 2, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 17,000 | $1.64M |
| Oct 1, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 17,000 | $1.66M |
| Sep 30, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 32,000 | $3.14M |
| Sep 29, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 34,000 | $3.34M |
| Sep 28, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 34,000 | $3.35M |
| Sep 25, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 27,000 | $2.66M |
| Sep 24, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 39,000 | $3.86M |
| Sep 23, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 30,000 | $2.98M |
| Sep 22, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 46,000 | $4.63M |
| Sep 21, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 33,000 | $3.23M |
| Sep 18, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 30,000 | $2.89M |
| Sep 17, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 34,000 | $3.35M |
| Sep 16, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 15,000 | $1.44M |
| Sep 15, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 34,000 | $3.28M |
| Sep 14, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 41,000 | $4.08M |
| Sep 11, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 45,000 | $4.36M |
| Sep 10, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 20,500 | $1.97M |
| Sep 9, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 36,000 | $3.52M |
| Sep 8, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 37,000 | $3.67M |
| Sep 4, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 31,500 | $3.26M |
| Sep 3, 2026 | Sahin Ugur Chief Executive Officer | Sale 10b5-1 plan | 45,000 | $4.63M |
| Apr 22, 2026 | Poetting Sierk Chief Operating Officer | Sale 10b5-1 plan | 50,000 | $5.53M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BioNTech SE
Free account. Everything above stays public.
Write why you follow BioNTech SE and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading